ClinicalTrials.gg
Not yet recruitingNCT06966089Updated May 11, 2025

ExosomeDx in MRI-negative Men With High PSA

An interventional study of Urinary ExoDx test and Transrectal ultrasound-guided prostate biopsy in Prostate Cancer, sponsored by Icahn School of Medicine at Mount Sinai. Not yet recruiting at 6 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
425
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai — 5 open to participants now, 7 under way, 1 of them phase 3. Prostatic Neoplasms · Icahn School of Medicine at Mount Sinai.

Planned enrollment
2nd of 12
425 · median 40
Started
2025
with 1 other
No phase
5 of 15
1 open now
Registered
12th of 15
by date

Among the 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 12th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prostatic Neoplasms by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

Magnetic resonance imaging (MRI) has become the current standard of care in risk stratifying men with an elevated Prostate-specific antigen (PSA) to determine who needs to undergo prostate biopsy, which is invasive and carries a 3-5% risk of serious infection. Recent data shows the negative predictive value of MRI to be only 77%, indicating that some men may inappropriately forego biopsy based on a negative MRI. Urinary exosomes can be captured and analyzed by the ExosomeDx (ExoDx) Prostate test, a urine based, gene signature derived from PCA3 (prostate cancer antigen 3) and ERG (erythroblast transformation-specific related gene), and SPDEF (SAM pointed domain-containing ETS transcription factor); ExoDx carries a 90% negative predictive value.

The use of ExoDx test among patients with negative MRIs has the potential to improve the risk stratification of patients with an elevated PSA in a way that the Urologist can more accurately determine which patients need to undergo prostate biopsy. In doing so, the Urologist can better risk-stratify which patients should undergo prostate biopsy and be exposed to the associated potential risks, and also be more confident about the safety of foregoing biopsy in those patients with negative MRI and negative ExoDx test.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Urinary Exosome
  • ExoDx Prostate test
  • ExosomeDx
  • ERG
  • Erythroblast Transformation-Specific Related Gene
  • SPDEF
  • SAM Pointed Domain-containing ETS Transcription Factor
  • Exosome Diagnostic Intelligence
  • EPI
  • Prostate cancer
  • Prostate Biopsy
  • Exosome
  • Prostate MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, an individual must meet all the following criteria;

  • Willingness to participate and provide signed and dated form
  • Male (sex)
  • Age ≥ 18 years
  • PSA screen-eligible, per investigator discretion

    • 45-75 years of age for average risk
    • 40-75 years of age for high risk
  • PSA ≥ 2.0 ng/mL and ≤ 10.0 ng/mL
  • MRI PIRADS score of 1 or 2
  • 0-1
  • Must have a negative urine culture prior to
  • No prior prostate biopsies within the last 5 years (biopsy-naïve)
  • Willingness to undergo a prostate biopsy as part of the diagnostic work-up
  • Digital rectal exam with no palpable nodules

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study;

  • Prior or current histologic or pathologic confirmed diagnosis of prostate cancer
  • Prior transrectal ultrasound within the last 5 years
  • Any prior cancer diagnosis within the last 5 years
  • On or predefined immunosuppressed state
  • A known coagulopathy predisposition to bleeding
  • Diagnoses of any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
  • Cognitive inability or psychiatric conditions that preclude informed decision making or compliance with study requirements (per investigator discretion)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
425 participants (estimated)

Study arms

  • Experimental
    Participants with elevated or rising PSA

    Participants who have been diagnosed with an elevated or rising PSA as determined by their urologist, and who have a negative (PIRADS 1 or 2) prostate MRI will be offered enrollment in this trial. ExoDx Study Kit will be collected onsite. Participants will then be scheduled for transrectal ultrasound-guided or transperineal 12-core prostate biopsy as per the standard diagnostic practice.

    Device: Urinary ExoDx test · Diagnostic Test: Transrectal ultrasound-guided prostate biopsy · Diagnostic Test: Transperineal 12-core prostate biopsy

Interventions

  • DeviceUrinary ExoDx test

    A urine sample for ExoDx Study Kit will be collected onsite and shipped to Exosome Diagnostic's laboratory.

  • Diagnostic testTransrectal ultrasound-guided prostate biopsy

    Participants will be scheduled for transrectal ultrasound-guided prostate biopsy as per the standard diagnostic practice after urinary test.

  • Diagnostic testTransperineal 12-core prostate biopsy

    Participants will be scheduled for transperineal 12-core prostate biopsy as per the standard diagnostic practice after urinary test.

06

What researchers measure

Primary outcomes

  1. Sensitivity

    Sensitivity is defined as the probability that clinically significant cancer is detected when it is cancer. Sensitivity = true positive cases / true positive cases + false negative cases

    Time frame: duration of study, average 3 months

  2. Specificity

    Specificity is defined as the probability that clinically significant cancer is not detected when it is not cancer. Specificity = true negative cases / true negative cases + false positive cases

    Time frame: duration of study, average 3 months

Secondary outcomes

  1. Cancer Detection Rate

    Cancer Detection Rate (CDR): Cancer detection rate is defined as the proportion of enrolled patients with histologically Gleason grade group 1+ cancers and as determined by the Investigator. Cancer detection rate = true positive (histologically Gleason grade 1+) / all tests performed

    Time frame: duration of study, average 3 months

  2. csPCa Detection Rate

    csPCa Detection Rate (csCDR): clinically significant cancer detection rate is defined as the proportion of enrolled patients with histologically Gleason grade group 2+ cancers. csPCa detection rate = true positive (histologically Gleason grade 2+) / all tests performed

    Time frame: duration of study, average 3 months

  3. Biopsy aversion rate

    Biopsy aversion rate is defined as the proportion of patients in whom the biopsy could have been potentially averted using ExosomeDx, as compared to decisions based on PSA density.

    Time frame: duration of study, average 3 months

  4. Net Benefit

    Decision curve analysis will be used to calculate the net benefit of adding ExoDx to PSA density (including kinetics and density) and MRI in the diagnostic workflow following. Net benefit is calculated across a range of threshold probabilities, defined as the minimum probability of disease at which further intervention would be warranted, as net benefit = sensitivity × prevalence - (1 - specificity) × (1 - prevalence) × w where w is the odds at the threshold probability.

    Time frame: duration of study, average 3 months

  5. Diagnostic Accuracy

    Accuracy is defined as the potential of ExoDx to correctly detect the presences or absence of disease. Diagnostic Accuracy = (True Positive) + True Negative / All) \* 100

    Time frame: duration of study, average 3 months

  6. Positive Predictive Value (PPV)

    Positive predictive value is defined as the probability that an elevated ExoDx actually has cancer. Positive Predictive Value = (True Positive)/(True Positive + False Positive)

    Time frame: duration of study, average 3 months

  7. Negative Predictive Value (NPV)

    Negative predictive value is defined as the probability a negative ExoDx test does not cancer. Negative Predictive Value = (True Negative)/(True Negative + False Negative)

    Time frame: duration of study, average 3 months

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Analytic code

Time frame: Immediately following publication. No end date.

Access criteria: Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Specify Other Mechanism Email proposal to Principal Investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2026, 12 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 11, 2025
StartEst.
Aug 2025
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06966089
Collaborators
Bio-Techne Corporation
Responsible party
Nikhil Waingankar (Associate Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
May 11, 2025
Start date
Aug 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
May 11, 2025

Study contacts

Nikhil Waingankar, MD
Contact
nikhil.waingankar@mountsinai.org
(718) 808-7777
Nikhil Waingankar, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion